Echo IQ appoints Dustin Haines as CEO to drive commercialisation strategy

Echo IQ Limited (ASX:EIQ) has appointed Mr. Dustin Haines as the Chief Executive Officer, effective from 10 January 2025. Mr. Haines, a leading healthcare executive with over 25 years' experience in commercialising innovative therapies, will be based in the US and will spearhead the Company's commercialisation and sales strategy, while pursuing expansion opportunities. This appointment follows the FDA clearance of EchoSolv in the US, positioning EIQ well to capitalize on uptake by commercial partners.

Executive Chairman's Perspective on Appointment of Dustin Haines

To have secured someone of Dustin's calibre to execute our stated commercialisation strategy highlights the considerable potential of the Company's technology in the US market. Dustin is joining the Company at a pivotal time in Echo IQ's growth and development and was selected because of his extensive experience in delivering commercial outcomes across the healthcare industry. As a US-based executive, we will have the ability to leverage his extensive network in the world's largest healthcare market to drive sales growth for EchoSolv.

Summary of Echo IQ's Appointment of Dustin Haines

Echo IQ Limited (ASX:EIQ) has appointed Mr. Dustin Haines as the Chief Executive Officer to lead the Company's commercialisation and sales strategy, focusing on the US market. Mr. Haines, with over 25 years' experience in the biotechnology and pharmaceutical sectors, brings a demonstrated track record of executing commercialisation opportunities, obtaining product reimbursement, and driving revenue growth. His appointment follows the FDA clearance of EchoSolv in the US, leaving EIQ well placed to capitalize on uptake by commercial partners. The Company is in advanced negotiations with large hospital groups, pharmaceutical companies, and device manufacturers regarding the uptake of EchoSolv and plans to leverage Mr. Haines' extensive network to further broaden its pipeline of opportunities in the US and internationally. The appointment of Mr. Haines signifies a significant step for Echo IQ in its pursuit of near term commercialisation opportunities and expansion in the healthcare industry.